CLL Coverage from Every Angle

William G. Wierda, MD, PhD, on Clinical Implications of Experimental CAR T-Cell Treatment in Relapsed/Refractory CLL/SLL

Posted: Thursday, August 1, 2019

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses study findings on the ability of a CD19-directed CAR T-cell therapy to eradicate minimal residual disease in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.